Drug
Tobemstomig clinical trials
Also written RO7247669.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How studies write it
Studies that test it under each name
Name
Studies by the year they started
9 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
Tiragolumab (4) · Atezolizumab (3) · Bevacizumab (1) · Tocilizumab (1) · Amezalpat (1) · Muzastotug (1) · Anti-LILRB2 Monoclonal Antibody IO-108 (1) · Imdatifan (1)
Studies
Open first, then newest update. How each study uses tobemstomig is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular CarcinomaTerminatedPhase 1/2Hoffmann-La RocheNCT05908786Written as Tobemstomig
- Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid TumorsActive, not recruitingPhase 1/2Hoffmann-La RocheNCT04140500Written as RO7247669
- A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerActive, not recruitingPhase 2Hoffmann-La RocheNCT05852691Written as Tobemstomig
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Active, not recruitingPhase 1/2Hoffmann-La RocheNCT04524871Written as Tobemstomig 2100 mg
- A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerActive, not recruitingPhase 2Hoffmann-La RocheNCT05645692Written as Tobemstomig
- A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung CancerCompletedPhase 2Hoffmann-La RocheNCT05775289Written as Tobemstomig
- A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the EsophagusCompletedPhase 2Hoffmann-La RocheNCT04785820Written as Tobemstomig
- A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic MelanomaCompletedPhase 2Hoffmann-La RocheNCT05419388Written as RO7247669
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)CompletedPhase 1/2Hoffmann-La RocheNCT05116202Written as RO7247669 2100 mg
Given in every arm · 1 — tobemstomig is usual care beside what is tested
Codes
What other systems call tobemstomig · ClinicalTrials.gg INT015775
- UNII (FDA) 93NRF4S9HRTOBEMSTOMIGOne source FDA
- NCI Thesaurus C173539TobemstomigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 93NRF4S9HR | TOBEMSTOMIG | One source FDA |
| NCI Thesaurus | C173539 | Tobemstomig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.